Elanco sells aqua business to Merck Animal Health for $1.3B cash

Elanco Animal Health Inc

Transaction valued at approx. 7.4x estimated 2023 revenue of $175M and adjusted EBITDA of $92M.
After-tax proceeds of $1.05B-$1.1B to be used to pay down Term Loan B debt, reducing interest expense ~$65M annually.
Pro forma net leverage ratio would have been ~5.0x for 2023, down from slight below midpoint of 5.5x-5.8x guidance.
Expected close around mid-2024, subject to regulatory approvals and customary conditions.
Divestiture includes ~280 employees, manufacturing sites in Canada and Vietnam, and R&D projects.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Elanco Animal Health Inc entered into Asset Purchase Agreement with Intervet International B.V. valued at approximately $1.3 billion (effective 2024-02-05).

Action: entry
Agreement: asset purchase
Counterparty: Intervet International B.V.
Value: approximately $1.3 billion
Effective: 2024-02-05

Exact text from the filing

On February 5, 2024, Elanco Animal Health Incorporated, an Indiana corporation (“Elanco”), and Intervet International B.V., a Dutch private company with limited liability (“Buyer”), entered into an Asset Purchase Agreement (the “Agreement”).

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001104659-24-010337

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.